TY  - JOUR
T1  - Bisphosphonates and innovative drugs in the prevention of skeletal complications secondary to metastatic prostate cancer
A1  - Nabil Ismaili
A1  - Ali Tahri
A1  - Rhizlane Belbaraka
JF  - Clinical Cancer Investigation Journal
JO  - Clin Cancer Investig J
SN  - 2278-0513
Y1  - 2013
VL  - 2
IS  - 4
DO  - 10.4103/2278-0513.121517
SP  - 294
EP  - 297
N2  - Over than 80% of patients with locally advanced prostate cancer will develop bone metastases during the disease management. These metastases are often responsible for complications that impaired the quality of life, impaired the prognosis and increased the mortality by prostate cancer (PC). Two drugs are currently approved by the scientific community in the prevention of skeletal complications secondary to castration-resistant prostate cancer metastatic to bone (CRPCMB), zoledronic acid at a dose of 4 mg intravenously every 3-4 weeks and denosumab at a dose of 120 mg subcutaneously every 4 weeks. This aim of the preset paper was to review the current literature on the mechanism of action, efficacy, and safety profile of these two classes of molecules in the management of CRPCMB.
UR  - https://ccij-online.org/article/bisphosphonates-and-innovative-drugs-in-the-prevention-of-skeletal-complications-secondary-to-metastatic-prostate-cancer-139
ER  -